GlassScriptPhysician profile
Matthew Nielsen
NPI 1700129707
$2,373.07
in general payments reported to CMS, 2019-2025
27 companies · $532 in 2025
The $532 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $285 · 2021: $309 · 2022: $197 · 2023: $165 · 2024: $123 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801 · Travel and Lodging: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.98 |
| Travel and Lodging | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $582.92 | 2019-2025 | Moses, Lithovue, Ams 800 Artificial Urinary Sphincter |
| Astellas Pharma US INC | $413.19 | 2019-2025 | Xtandi |
| Karl Storz Endoscopy-America | $350.73 | 2019-2022 | |
| Medtronic, INC. | $122.99 | 2024 | Interstim |
| Neotract INC. | $117.60 | 2020 | |
| Urogen Pharma, INC. | $112.11 | 2023-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $75.90 | 2019-2021 | |
| Coloplast Corp | $61.05 | 2020-2021 | |
| Olympus America INC. | $51.25 | 2025 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $49.35 | 2019-2025 | |
| C. R. Bard, INC. & Subsidiaries | $43.97 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $39.49 | 2019 | |
| Rochester Medical Corporation | $37.84 | 2021 | |
| Pfizer INC. | $36.51 | 2019-2025 | |
| Steris Corporation | $32.65 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $32.29 | 2019-2025 | Iovera, Exparel |
| Progenics Pharmaceuticals, INC. | $29.06 | 2022 | |
| Sumitomo Pharma America, INC. | $26.35 | 2025 | Gemtesa |
| Allergan, INC. | $26.25 | 2019 | |
| Antares Pharma, INC. | $25.07 | 2025 | Xyosted |
| Zyla Life Sciences, INC. | $17.70 | 2019 | |
| Tolmar, INC. | $17.29 | 2025 | Eligard, Jatenzo |
| Myriad Genetic Laboratories, INC. | $15.99 | 2021 | |
| Procept Biorobotics Corporation | $14.59 | 2025 | |
| Photocure INC | $14.40 | 2025 | Cysview |
| Janssen Biotech, INC. | $13.98 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nielsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.